Pacira Pharmaceuticals Inc (PCRX)

Return on equity (ROE)

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net income	US$ in thousands	41,955	15,909	41,980	145,523	-11,016
Total stockholders’ equity	US$ in thousands	870,130	775,010	730,408	619,688	354,944
ROE		4.82%	2.05%	5.75%	23.48%	-3.10%

December 31, 2023 calculation

ROE = Net income ÷ Total stockholders’ equity
= $41,955K ÷ $870,130K
= 4.82%

Pacira BioSciences Inc's return on equity (ROE) has displayed significant fluctuations over the past five years. In 2023, the ROE stood at 4.82%, showing a slight improvement compared to the previous year's 2.05%. However, this figure is notably lower than the ROE reported in 2021, which was 5.75%. The most significant ROE observed in the last five years was in 2020, reaching 23.48%, showcasing a substantial performance in generating profits relative to shareholders' equity. In contrast, the company experienced negative ROE in 2019, at -3.10%, indicating a period of unprofitability and potential operational challenges. Overall, Pacira BioSciences Inc's ROE trend suggests varying levels of profitability and efficiency in utilizing shareholders' equity to generate returns during the analyzed period.